rs1456129845
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 5P and 4B. PVS1_StrongPP5BS2
The ENST00000301761.7(SDHAF2):c.355dup(p.Tyr119LeufsTer8) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000868 in 1,612,996 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. I118I) has been classified as Likely benign.
Frequency
Consequence
ENST00000301761.7 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SDHAF2 | NM_017841.4 | c.355dup | p.Tyr119LeufsTer8 | frameshift_variant | 3/4 | ENST00000301761.7 | NP_060311.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SDHAF2 | ENST00000301761.7 | c.355dup | p.Tyr119LeufsTer8 | frameshift_variant | 3/4 | 1 | NM_017841.4 | ENSP00000301761 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152082Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251486Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135918
GnomAD4 exome AF: 0.00000685 AC: 10AN: 1460914Hom.: 0 Cov.: 33 AF XY: 0.00000275 AC XY: 2AN XY: 726842
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152082Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74286
ClinVar
Submissions by phenotype
Hereditary pheochromocytoma-paraganglioma Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 20, 2023 | This sequence change creates a premature translational stop signal (p.Tyr119Leufs*8) in the SDHAF2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 48 amino acid(s) of the SDHAF2 protein. This variant is present in population databases (no rsID available, gnomAD 0.004%). This premature translational stop signal has been observed in individual(s) with a right carotid body paranglioma (PMID: 22241717). ClinVar contains an entry for this variant (Variation ID: 403423). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Sep 23, 2024 | This variant inserts 1 nucleotide in exon 3 of the SDHAF2 gene, creating a frameshift and premature translation stop signal. This variant is expected to escape nonsense-mediated decay but result in a non-functional protein product. This variant impacts the C-terminal 48 amino acids. Functional studies have shown that a deletion of the C-terminal 15 amino acids of SDHAF2 abolished SDHA-SDHAF2 interaction and SDHA flavination (PMID: 32887801). This variant has been reported in an individual affected with a right carotid body paraganglioma (PMID: 22241717). This variant has been identified in 2/282866 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
Paragangliomas 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jun 13, 2023 | - - |
SDHAF2-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 29, 2024 | The SDHAF2 c.355dupT variant is predicted to result in a frameshift and premature protein termination (p.Tyr119Leufs*8). This variant has been reported in patients with paraganglioma/pheochromocytoma tumors (Table S1 in Evenepoel L et al 2014. PubMed ID: 25394176; reported as c.357_358insT Piccini et al. 2012. PubMed ID: 22241717). This variant occurs in the 2nd to last exon and may not result in non-sense mediated decay. This variant is reported in 0.0040% of alleles in individuals of African descent in gnomAD. Frameshift variants in SDHAF2 are expected to be pathogenic. This variant is interpreted as likely pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | SDHAF2: PVS1:Strong, PM2, PS4:Moderate - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 11, 2024 | The c.355dupT (p.Y119Lfs*8) alteration, located in exon 3 (coding exon 3) of the SDHAF2 gene, consists of a duplication of T at position 355, causing a translational frameshift with a predicted alternate stop codon after 8 amino acids. This alteration occurs at the 3' terminus of theSDHAF2 gene, is not expected to trigger nonsense-mediated mRNA decay, and impacts the last 48 amino acids of the protein. However, premature stop codons are typically deleterious in nature and a significant portion of the protein is affected (Ambry internal data). Based on data from gnomAD, this allele has an overall frequency of 0.001% (2/282866) total alleles studied. The highest observed frequency was 0.004% (1/24968) of African alleles. This variant (reported as c.357_358insT in one study) has been detected in two unrelated individuals with a paraganglioma (Piccini, 2012; Evenepoel, 2015). Based on internal structural analysis, this mutation removes a large portion of the SDHAF2-SDHA interface and is likely to disrupt protein function and stability (Hao, 2009; Eletsky, 2012; Sharma, 2020). Based on the available evidence, this alteration is classified as pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jun 23, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: LOF not established disease mechanism for this gene - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at